TYK Medicines Received the Second Clinical Approval This Year with High Efficiency

An Open-label, Single-arm, and Multicenter Phase I Study to Evaluate the Safety, Tolerance, Pharmacokinetics, and Preliminary Efficacy of TY-9591 Tablets for the Treatment of Advanced Non-Small Cell Lung Cancer (NSCLC)

[recruitment] A Phase I Study to Evaluate the Safety, Tolerance, and Pharmacokinetics of TY-302 Capsule for the Treatment of Advanced Solid Tumors in China

TY-302 capsule is a CDK4/6 inhibitor

TYK Medicines Successfully Certified as Zhejiang Science and Technology-Based Small and Medium-sized Enterprise

TYK Medicines has Officially Established the Huzhou Academician Expert Workstation

A Discussion Panel Regarding the Phase I Clinical Trial Protocol of the TY-9591 Program was Held in Shanghai

On August 14, 2019, a discussion panel regarding the phase I clinical trial protocol of the TY-9591